Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts

Nature Genetics volumeΒ 41,Β pages 47–55 (2009) Cite this article

View saved research

Abstract

Recent genome-wide association (GWA) studies of lipids have been conducted in samples ascertained for other phenotypes, particularly diabetes. Here we report the first GWA analysis of loci affecting total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides sampled randomly from 16 population-based cohorts and genotyped using mainly the Illumina HumanHap300-Duo platform. Our study included a total of 17,797–22,562 persons, aged 18–104 years and from geographic regions spanning from the Nordic countries to Southern Europe. We established 22 loci associated with serum lipid levels at a genome-wide significance level (P < 5 Γ— 10βˆ’8), including 16 loci that were identified by previous GWA studies. The six newly identified loci in our cohort samples are ABCG5 (TC, P = 1.5 Γ— 10βˆ’11; LDL, P = 2.6 Γ— 10βˆ’10), TMEM57 (TC, P = 5.4 Γ— 10βˆ’10), CTCF-PRMT8 region (HDL, P = 8.3 Γ— 10βˆ’16), DNAH11 (LDL, P = 6.1 Γ— 10βˆ’9), FADS3-FADS2 (TC, P = 1.5 Γ— 10βˆ’10; LDL, P = 4.4 Γ— 10βˆ’13) and MADD-FOLH1 region (HDL, P = 6 Γ— 10βˆ’11). For three loci, effect sizes differed significantly by sex. Genetic risk scores based on lipid loci explain up to 4.8% of variation in lipids and were also associated with increased intima media thickness (P = 0.001) and coronary heart disease incidence (P = 0.04). The genetic risk score improves the screening of high-risk groups of dyslipidemia over classical risk factors.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Explore related subjects

Discover the latest articles and news in related subjects.

References

  1. Pilia, G. et al. Heritability of cardiovascular and personality traits in 6,148 Sardinians. PLoS Genet. 2, e132 (2006).

    ArticleΒ  Google ScholarΒ 

  2. Kannel, W.B.D.T., Kagan, A., Revotskie, N. & Stokes, J.I. Factors of risk in the development of coronary heart disease–six year follow-up experience. The Framingham Study. Ann. Intern. Med. 55, 33–50 (1961).

    ArticleΒ  CASΒ  Google ScholarΒ 

  3. Miller, N.E. & Letter, M.G. High-density lipoprotein and atherosclerosis. Lancet 1, 1033 (1975).

    ArticleΒ  CASΒ  Google ScholarΒ 

  4. Friedlander, Y.A.A., Newman, B., Edwards, K., Mayer-Davis, E.J. & King, M.-C. Heritability of longitudinal changes in coronary-heart-disease risk factors in women twins. Am. J. Hum. Genet. 60, 1502–1512 (1997).

    ArticleΒ  CASΒ  Google ScholarΒ 

  5. Kathiresan, S., Musunuru, K. & Orho-Melander, M. Defining the spectrum of alleles that contribute to blood lipid concentrations in humans. Curr. Opin. Lipidol. 19, 122–127 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  6. Kooner, J. et al. Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat. Genet. 40, 149–151 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  7. Kathiresan, S. et al. Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat. Genet. 40, 189–197 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  8. Willer, C.J. et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat. Genet. 40, 161–169 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  9. Wallace, C. et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am. J. Hum. Genet. 82, 139–149 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  10. Sandhu, M., Waterworth, D., Debenham, S., Wheeler, W. & Papadakis, K. LDL-cholesterol concentrations: a genome-wide association study. Lancet 371, 483–491 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  11. Heid, I. et al. A genome-wide association analysis of HDL cholesterol in the population-based KORA Study sheds new light on intergenic regions. Circulation. Cardiovas.Genet. 1, 10–20 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  12. Sing, C. & Davignon, J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am. J. Hum. Genet. 37, 268–285 (1985).

    CASΒ  PubMedΒ  PubMed CentralΒ  Google ScholarΒ 

  13. Law, S. et al. The molecular biology of human apoA-I, apoA-II, apoC-II and apoB. Adv. Exp. Med. Biol. 201, 151–162 (1986).

    CASΒ  PubMedΒ  Google ScholarΒ 

  14. Kathiresan, S. et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N. Engl. J. Med. 358, 1240–1249 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  15. Wang, K., Li, M. & Bucan, M. Pathway-based approaches for analysis of genome-wide association studies. Am. J. Hum. Genet. 81, 1278–1283 (2007).

    ArticleΒ  CASΒ  Google ScholarΒ 

  16. Rudkowska, I. & Jones, P. Polymorphisms in ABCG5/G8 transporters linked to hypercholesterolemia and gallstone disease. Nutr. Rev. 66, 343–348 (2008).

    ArticleΒ  Google ScholarΒ 

  17. Sabatti, C. et al. Genome-wide association analysis of metabolic phenotypes in a birth cohort from a founder population. Nat. Genet. advance online publication, doi:10.1038/ng.271 (7 December 2008).

  18. Weiss, L., Pan, L., Abney, M. & Ober, C. The sex-specific genetic architecture of quantitative traits in humans. Nat. Genet. 38, 218–222 (2006).

    ArticleΒ  CASΒ  Google ScholarΒ 

  19. Tunstall-Pedoe, H. et al. MONICA Monograph and Multimedia Sourcebook (World Health Organization, Geneva, 2003).

    Google ScholarΒ 

  20. Endo, A. The discovery and development of HMG-CoA reductase inhibitors. J. Lipid Res. 33, 1569–1582 (1992).

    CASΒ  Google ScholarΒ 

  21. Kasper, D. Harrison's Principles of Internal Medicine (McGraw-Hill, New York, 2005).

    Google ScholarΒ 

  22. Chasman, D. et al. Pharmacogenetic study of statin therapy and cholesterol reduction. J. Am. Med. Assoc. 291, 2821–2827 (2004).

    ArticleΒ  CASΒ  Google ScholarΒ 

  23. Howard, B., Ruotolo, G. & Robbins, D. Obesity and dyslipidemia. Endocrinol. Metab. Clin. North Am. 32, 855–867 (2003).

    ArticleΒ  CASΒ  Google ScholarΒ 

  24. Janssens, A. & van Duijn, C. Genome-based prediction of common diseases: advances and prospects. Hum. Mol. Genet. 17, 166–173 (2008).

    ArticleΒ  Google ScholarΒ 

  25. Anderson, K., Odell, P., Wilson, P. & Kannel, W. Cardiovascular disease risk profiles. Am. Heart J. 121, 293–298 (1991).

    ArticleΒ  CASΒ  Google ScholarΒ 

  26. Hippisley-Cox, J., Coupland, C., Vinogradova, Y., Robson, J. & Brindle, P. Performance of the QRISK cardiovascular risk prediction algorithm in an independent UK sample of patients from general practice: a validation study. Heart 94, 34–39 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  27. Peltonen, L. GenomEUtwin: a strategy to identify genetic influences on health and disease. Twin Res. 6, 354–360 (2003).

    ArticleΒ  Google ScholarΒ 

  28. Rantakallio, P. Groups at risk in low birth weight infants and perinatal mortality. Acta Paediatr. Scand. 193, 1 (1969).

    Google ScholarΒ 

  29. Hofman, A. et al. The Rotterdam Study: objectives and design update. Eur. J. Epidemiol. 22, 819–829 (2007).

    ArticleΒ  Google ScholarΒ 

  30. Friedewald, W.T., Levy, R.I. & Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502 (1972).

    CASΒ  PubMedΒ  Google ScholarΒ 

  31. Pardo, L.M., MacKay, I., Oostra, B., van Duijn, C.M. & Aulchenko, Y.S. The effect of genetic drift in a young genetically isolated population. Ann. Hum. Genet. 69, 288–295 (2005).

    ArticleΒ  CASΒ  Google ScholarΒ 

  32. Pattaro, C. et al. The genetic study of three population microisolates in South Tyrol (MICROS): study design and epidemiological perspectives. BMC Med. Genet. 8, 29 (2007).

    ArticleΒ  Google ScholarΒ 

  33. Rudan, I., Campbell, H. & Rudan, P. Genetic epidemiological studies of eastern Adriatic Island isolates, Croatia: objective and strategies. Coll. Antropol. 23, 531–546 (1999).

    CASΒ  PubMedΒ  Google ScholarΒ 

  34. Boomsma, D. et al. Genome-wide association of major depression: description of samples for the GAIN Major Depressive Disorder Study: NTR and NESDA biobank projects. Eur. J. Hum. Genet. 16, 335–342 (2008).

    ArticleΒ  CASΒ  Google ScholarΒ 

  35. Wichmann, H., Gieger, C. & Illig, T. KORA-gen–resource for population genetics, controls and a broad spectrum of disease phenotypes. Gesundheitswesen 67, S26–S30 (2005).

    ArticleΒ  Google ScholarΒ 

  36. Steemers, F. et al. Whole-genome genotyping with the single-base extension assay. Nat. Methods 3, 31–33 (2006).

    ArticleΒ  CASΒ  Google ScholarΒ 

  37. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analysis. Am. J. Hum. Genet. 81, 559–575 (2007).

    ArticleΒ  CASΒ  Google ScholarΒ 

  38. Aulchenko, Y.S., Ripke, S., Isaacs, A. & van Duijn, C.M. GenABEL: an R library for genome-wide association analysis. Bioinformatics 23, 1294–1296 (2007).

    ArticleΒ  CASΒ  Google ScholarΒ 

  39. Price, A.L. et al. Principal components analysis corrects for stratification in genome-wide association studies. Nat. Genet. 38, 904–909 (2006).

    ArticleΒ  CASΒ  Google ScholarΒ 

  40. Bacanu, S.A., Devlin, B. & Roeder, K. The power of genomic control. Am. J. Hum. Genet. 66, 1933–1944 (2000).

    ArticleΒ  CASΒ  Google ScholarΒ 

  41. Scott, L. et al. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316, 1341–1345 (2007).

    ArticleΒ  CASΒ  Google ScholarΒ 

Download references

Acknowledgements

Above all, we thank study participants for making this work possible. We thank H.-Y. Shen and M. Allen for ENGAGE project management and M. Krestyaninova for IT-system setup.

The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013)/grant agreement HEALTH-F4-2007-201413 by the European Commission under the programme 'Quality of Life and Management of the Living Resources' of 5th Framework Programme (no. QLG2-CT-2002-01254). The Finnish Heart Association (M.P., L.P.) is gratefully acknowledged for its financial support. L.P. and J.K. have been supported by the Academy of Finland Centre of Excellence in Complex Disease Genetics.

NFBC genotyping was supported on NHLBI grant 5R01HL087679-02 through the STAMPEED program.

EUROSPAN (European Special Populations Research Network) was supported by European Commission FP6 STRP grant number 018947 (LSHG-CT-2006-01947).

For the MICROS study in South Tyrol, we thank the primary care practitioners R. Stocker, S. Waldner, T. Pizzecco, J. Plangger, U. Marcadent and the personnel of the Hospital of Silandro (Department of Laboratory Medicine) for their participation and collaboration in the research project. In South Tyrol, the study was supported by the Ministry of Health of the Autonomous Province of Bolzano and the South Tyrolean Sparkasse Foundation.

NTR/NESDA was supported by β€œGenetic basis of anxiety and depression” program (NWO 904-61-090); Twin-family database for behavior genomics studies (NWO 480-04-004); Center for Medical Systems Biology (NWO Genomics); Spinozapremie (SPI 56-464-14192); Centre for Neurogenomics and Cognitive Research (CNCR-VU); Genome-wide analyses of European twin and population cohorts (EU/QLRT-2001-01254); Geestkracht program of ZonMW (10-000-1002); and matching funds from universities and mental health care institutes involved in NESDA (GGZ Buitenamstel-Geestgronden, Rivierduinen, University Medical Center Groningen, GGZ Lentis, GGZ Friesland, GGZ Drenthe). Major funding for this project is from the Genetic Association Information Network of the Foundation for the US National Institutes of Health, a public-private partnership between the NIH and Pfizer, Affymetrix and Abbott Laboratories.

The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum MΓΌnchen, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). Part of this work was financed by the German National Genome Research Network (NGFN) and by the β€œGenomics of Lipid-associated Disorders – GOLD” of the β€œAustrian Genome Research Programme GEN-AU”. The KORA research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. We gratefully acknowledge the contribution of P. Lichtner, G. Eckstein and T. Strom and all other members of the Helmholtz Zentrum MΓΌnchen genotyping staff in generating and analyzing the SNP dataset. We thank all members of field staffs who were involved in the planning and conduct of the MONICA/KORA Augsburg studies. Finally, we express our appreciation to all study participants.

Genome-wide genotyping of the Rotterdam Study was supported by NWO (175.010.2005.011). The Vis study in the Croatian island of Vis was supported through the grants from the Medical Research Council UK to H.C., A.W. and I.R.; and Ministry of Science, Education and Sport of the Republic of Croatia to I.R. (number 108-1080315-0302). The ERF study was supported by grants from The Netherlands Organisation for Scientific Research, Erasmus MC and the Centre for Medical Systems Biology (CMSB). We are grateful to all study participants and their relatives, general practitioners and neurologists for their contributions and to P. Veraart for her help in genealogy, J. Vergeer for the supervision of the laboratory work and P. Snijders for his help in data collection. The Northern Swedish Population Health Study was funded by the Swedish Medical Research Council and the European Commission through the EUROSPAN project. We are greatly indebted to the participants in the study. The ORCADES study was supported by the Scottish Executive Health Department, the Royal Society and the Wellcome Trust Clinical Research Facility. We would like to acknowledge the data collection team in Orkney, the clerical team in Edinburgh and the people of Orkney.

Author information

Author notes

  1. Yurii S Aulchenko and Samuli Ripatti: These authors contributed equally to this work.

Authors and Affiliations

  1. Department of Epidemiology and Biostatistics, Erasmus University Medical Center, P.O. Box 2040, Rotterdam, 3000, CA, The Netherlands

    Yurii S Aulchenko,Β A Cecile J W Janssens,Β Albert Hofman,Β Aaron Isaacs,Β Eric J G Sijbrands,Β Jacqueline C M WittemanΒ &Β Cornelia M van Duijn

  2. National Public Health Institute, Biomedicum, P.O. Box 104, Helsinki, 00251, Finland

    Samuli Ripatti,Β Ida Lindqvist,Β Markus Perola,Β Kaisa SilanderΒ &Β Leena Peltonen

  3. FIMM, Institute for Molecular Medicine, Finland, Biomedicum, P.O.Box 104, Helsinki, 00251, Finland

    Samuli Ripatti,Β Ida Lindqvist,Β Jaakko Kaprio,Β Juha SaharinenΒ &Β Leena Peltonen

  4. Department of Biological Psychology, VU University Amsterdam, Van der Boechorststraat 1, Amsterdam, 1081, BT, The Netherlands

    Dorret Boomsma,Β Gonneke Willemsen,Β Jouke-Jan HottengaΒ &Β Eco J C de Geus

  5. Helmholtz-Center Munich, Institute of Epidemiology, IngolstÀdter Landstraße 1, Neuherberg, D-85764, Germany

    Iris M Heid,Β Christian Gieger,Β Angela DΓΆringΒ &Β H-Erich Wichmann

  6. University of Munich, IBE, Chair of Epidemiology, Munich, D-81377, Germany

    Iris M HeidΒ &Β H-Erich Wichmann

  7. Institute of Genetic Medicine, EURAC research, Viale Druso 1, Bolzano, 39100, Italy

    Peter P Pramstaller,Β Fabio Marroni,Β Cristian Pattaro,Β Irene PichlerΒ &Β Andrew A Hicks

  8. Department of Neurology, General Central Hospital, Via Bohler 5, Bolzano, 39100, Italy

    Peter P Pramstaller

  9. Department of Neurology, University of LΓΌbeck, Ratzeburger Allee 160, LΓΌbeck, 23538, Germany

    Peter P Pramstaller

  10. Department of Psychiatry, EMGO Institute, Institute of Neuroscience, VU Medical Center, Amsterdam, The Netherlands

    Brenda W J H PenninxΒ &Β Johannes H Smit

  11. Public Health Sciences, Community Health Sciences, University of Edinburgh, Medical School, Teviot Place, Edinburgh, EH8 9AG, UK

    James F Wilson,Β Harry CampbellΒ &Β Igor Rudan

  12. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, Edinburgh, EH4 2XU, UK

    James F Wilson,Β Caroline Hayward,Β Veronique Vitart,Β Alan WrightΒ &Β Nick Hastie

  13. Twin Research and Genetic Epidemiology Unit, King's College London, St Thomas' Hospital Campus, Strand, London, WC2R 2LS, UK

    Tim SpectorΒ &Β Mario Falchi

  14. Genetic Epidemiology Unit, Queensland Institute of Medical Research, PO Royal Brisbane Hospital, Queensland, 4029, Australia

    Nicholas G Martin,Β Grant W MontgomeryΒ &Β John Whitfield

  15. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177, Sweden

    Nancy L PedersenΒ &Β Patrik Magnusson

  16. Institute of Regional Health Research and the Danish Twin Registry, Institute of Public Health, University of Southern Denmark, J. B. WinslΓΈws Vej 9B, Odense, DK-5000, Denmark

    Kirsten Ohm Kyvik

  17. Department of Public Health, Faculty of Medicine, P.O. Box 41, FIN-00014 University of Helsinki, Helsinki, Finland

    Jaakko Kaprio

  18. Department of Mental Health and Alcohol Research, National Public Health Institute, Mannerheimintie 166, Helsinki, FIN-00300, Finland

    Jaakko Kaprio

  19. Department of Psychiatry, Center for Neurobehavioral Genetics, The Jane and Terry Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine, University of California, 695 Charles E. Young Drive South, Room 3506, Los Angeles, 90095, California, USA

    Nelson B Freimer

  20. Department of Epidemiology and Public Health, Imperial College London, St Mary's Campus, Norfolk Place, London, W2 1PG, UK

    Marjo-Riitta JarvelinΒ &Β Paul Elliott

  21. Department of Public Health Science and General Practice, University of Oulu, Finland

    Marjo-Riitta Jarvelin

  22. Department of Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, S-751 85, Sweden

    Ulf Gyllensten,Β Γ…sa JohanssonΒ &Β Inger Jonasson

  23. Croatian Centre for Global Health, University of Split Medical School, Soltanska 2, Split, 21000, Croatia

    Igor Rudan

  24. Institute for Clinical Medical Research, University Hospital β€œSestre Milosrdnice”, Vinogradska 29, Zagreb, 10000, Croatia

    Igor Rudan

  25. Genomic Medicine, Imperial College London, South Kensington Campus, London, SW7 2AZ, UK

    Mario Falchi

  26. Department of Internal Medicine, Erasmus University Medical Center, P.O. Box 2040, Rotterdam, 3000, CA, The Netherlands

    Eric J G SijbrandsΒ &Β Andre G Uitterlinden

  27. Department of Clinical Genetics. Erasmus University Medical Center, P.O. Box 2040, Rotterdam, 3000, CA, The Netherlands

    Ben A Oostra

  28. Department of Biochemistry, University Hospital Oulu, Oulu, 90220, Finland

    Aimo Ruokonen

  29. Department of Human Genetics, UCLA School of Medicine, University of California, 695 Charles E. Young Drive South, Los Angeles, 90095, California, USA

    Chiara Sabatti

  30. Helmholtz-Center Munich, Institute of Human Genetics, IngolstÀdter Landstraße 1, Neuherberg, D-85764, Germany

    Thomas Meitinger

  31. Technical University Munich, Institute of Human Genetics, Munich, D-81675, Germany

    Thomas Meitinger

  32. Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Innsbruck Medical University, Schoepfstrasse 41, Innsbruck, A-6020, Austria

    Florian Kronenberg

  33. Wellcome Trust Centre for Human Genetics, University of Oxford, Roosevelt Drive, Oxford, OX3 7BN, UK

    Mark I McCarthy

  34. Oxford Centre for Diabetes, Endocrinology and Medicine, University of Oxford, Churchill Hospital, Oxford, OX3 7LJ, UK

    Mark I McCarthy

  35. The Broad Institute, Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, 02142, Massachusetts, USA

    Leena Peltonen

  36. Wellcome Trust Sanger Institute Wellcome Trust Genome Campus, Hinxton, CB10 1SA, Cambridge, UK

    Leena Peltonen

Consortia

the ENGAGE Consortium

  • Yurii S Aulchenko
  • ,Β Samuli Ripatti
  • ,Β Ida Lindqvist
  • ,Β Dorret Boomsma
  • ,Β Iris M Heid
  • ,Β Peter P Pramstaller
  • ,Β Brenda W J H Penninx
  • ,Β A Cecile J W Janssens
  • ,Β James F Wilson
  • ,Β Tim Spector
  • ,Β Nicholas G Martin
  • ,Β Nancy L Pedersen
  • ,Β Kirsten Ohm Kyvik
  • ,Β Jaakko Kaprio
  • ,Β Albert Hofman
  • ,Β Nelson B Freimer
  • ,Β Marjo-Riitta Jarvelin
  • ,Β Ulf Gyllensten
  • ,Β Harry Campbell
  • ,Β Igor Rudan
  • ,Β Γ…sa Johansson
  • ,Β Fabio Marroni
  • ,Β Caroline Hayward
  • ,Β Veronique Vitart
  • ,Β Inger Jonasson
  • ,Β Cristian Pattaro
  • ,Β Alan Wright
  • ,Β Nick Hastie
  • ,Β Irene Pichler
  • ,Β Andrew A Hicks
  • ,Β Mario Falchi
  • ,Β Gonneke Willemsen
  • ,Β Jouke-Jan Hottenga
  • ,Β Eco J C de Geus
  • ,Β Grant W Montgomery
  • ,Β John Whitfield
  • ,Β Patrik Magnusson
  • ,Β Juha Saharinen
  • ,Β Markus Perola
  • ,Β Kaisa Silander
  • ,Β Aaron Isaacs
  • ,Β Eric J G Sijbrands
  • ,Β Andre G Uitterlinden
  • ,Β Jacqueline C M Witteman
  • ,Β Ben A Oostra
  • ,Β Paul Elliott
  • ,Β Aimo Ruokonen
  • ,Β Chiara Sabatti
  • ,Β Christian Gieger
  • ,Β Thomas Meitinger
  • ,Β Florian Kronenberg
  • ,Β Angela DΓΆring
  • ,Β H-Erich Wichmann
  • ,Β Johannes H Smit
  • ,Β Mark I McCarthy
  • ,Β Cornelia M van Duijn
  • Β &Β Leena Peltonen

Contributions

The study was designed by L.P., C.M.v.D., Y.S.A. and S.R. Genotype and phenotype information were collected by D.B., I.M.H., C.P., B.W.J.H.P., I.R., T.S., N.G.M., N.L.P., K.O.K., J.K., A.H., N.B.F., M.-R.J., U.G., H.C., J.F.W., Γ….J., F.M., C.H., V.V., I.J., P.P.P., A.W., N.H., I.P., A.A.H., M.F., G.W., J.-J.H., E.J.C.d.G., G.W.M., J.W., P.M., M.P., K.S., A.I., E.J.G.S., A.G.U., J.C.M.W., B.A.O., P.E., A.R., C.S., C.G., T.M., F.K., A.D., H.-E.W., J.H.S., M.I.M., C.M.v.D. and L.P. Statistical analysis was performed by Y.S.A., S.R., I.L., A.C.J.W.J., J.-J.H. and J.S. The manuscript was written by Y.S.A., S.R., A.C.J.W.J., C.M.v.D. and L.P. All authors reviewed the manuscript.

Corresponding author

Correspondence to Leena Peltonen.

Supplementary information

Supplementary Text and Figures (download PDF )

Supplementary Tables 1 and 2 and Supplementary Figures 1–6 (PDF 1020 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

the ENGAGE Consortium. Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts. Nat Genet 41, 47–55 (2009). https://doi.org/10.1038/ng.269

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/ng.269

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter β€” what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing